Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Autoimmune hepatitis is characterized by autoantibodies, hypergammaglobulinemia, and interface hepatitis on histological examination. The features lack diagnostic specificity, and other diseases that may resemble autoimmune hepatitis must be excluded. The clinical presentation may be acute, acute severe (fulminant), or asymptomatic; conventional autoantibodies may be absent; centrilobular necrosis and bile duct changes may be present; and the disease may occur after liver transplantation or with features that suggest overlapping disorders. The diagnostic criteria have been codified, and diagnostic scoring systems can support clinical judgment. Nonstandard autoantibodies, including antibodies to actin, α-actinin, soluble liver antigen, perinuclear antineutrophil antigen, asialoglycoprotein receptor, and liver cytosol type 1, are tools that can support the diagnosis, especially in patients with atypical features. Prednisone or prednisolone in combination with azathioprine is the preferred treatment, and strategies using these medications in various doses can ameliorate treatment failure, incomplete response, drug intolerance, and relapse after drug withdrawal. Budesonide, mycophenolate mofetil, and calcineurin inhibitors can be considered in selected patients as frontline or salvage therapies. Molecular (recombinant proteins and monoclonal antibodies), cellular (adoptive transfer and antigenic manipulation), and pharmacological (antioxidants, antifibrotics, and antiapoptotic agents) interventions constitute future directions in management. The evolving knowledge of the pathogenic pathways and the advances in technology promise new management algorithms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“Antioxidants (N-acetylcysteine, S-adenosyl-Lmethionine, and vitamin E) have already been shown in clinical experiences to decrease histological activity, TGF-β production, and fibrosis in NAFLD (Table 8).(324,325) They have also improved mortality in alcoholic cirrhosis,(326) and enhanced early viral responses in chro…”
BackgroundAlvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903
Self-citationSimplified criteria for the diagnosis of autoimmune hepatitis
Hennes, E. M., Zeniya, M., Czaja, A. J., Parés, A., Dalekos, G. N., Krawitt, E. L., Bittencourt, P. L., Porta, G., Boberg, K. M., Hofer, H., et al. (2008) · Hepatology · doi:10.1002/hep.22322 · Cited by 1,901
Self-citationDiagnosis and management of autoimmune hepatitis
Manns, M. P., Czaja, A. J., Gorham, J. D., Krawitt, E. L., Mieli-Vergani, G., Vergani, D., & Vierling, J. M. (2010) · Hepatology · doi:10.1002/hep.23584 · Cited by 1,442
Self-citationAnti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Chazouillères, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., & Poupon, R. (1998) · Hepatology · doi:10.1002/hep.510280203 · Cited by 746 · cited 1×
“Corticosteroids in combination with low dose ursodeoxycholic acid (13 to 15 mg/kg daily) is a common management strategy endorsed by the major liver societies.(105,130-132) The gold standard for the diagnosis is clinical judgment, and the strongest independent predictor of an overlap syndrome is the liver tissue exami…”
BackgroundGregorio, G. (2001) · Hepatology · doi:10.1053/jhep.2001.22131 · Cited by 692 · cited 1×
“2) Antibodies to liver kidney microsome 1 Antibodies to LKM1 are present in 3% of North American adults(149,156) and 14% to 38% of British children with autoimmune hepatitis (Table 4).(11,163) They can also be demonstrated in 0% to 2% of North American patients(156,164) and 10% of European patients with chronic hepati…”
BackgroundBoberg, K. M., Chapman, R. W., Hirschfield, G. M., Lohse, A. W., Manns, M. P., & Schrumpf, E. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.002 · Cited by 555 · cited 2×
“They have been used inappropriately to determine the presence of autoimmune hepatitis in patients with PBC,(144-146) and this application has been discouraged.(130) The scoring systems have also been used but not validated in”
BackgroundMethodMechanisms of action of mycophenolate mofetil
Allison, A. (2005) · Lupus · doi:10.1177/096120330501400102 · Cited by 480 · cited 1×
“Mycophenolate mofetil has side effects in 3% to 34% of patients, including cytopenia, which may resemble those of azathioprine, and it should be administered with caution or avoided in cytopenic patients.(49,260,261) It also has well documented teratogenic effects that preclude its use in pregnancy.”
BackgroundSmall-duct primary sclerosing cholangitis: a long-term follow-up study
Angulo, P., Maor-Kendler, Y., & Lindor, K. D. (2002) · Hepatology · doi:10.1053/jhep.2002.33202 · Cited by 213
Autoimmune hepatitis with incidental histologic features of bile duct injury
Czaja, A. J., & Carpenter, H. A. (2001) · Hepatology · doi:10.1053/jhep.2001.27562 · Cited by 189
Self-citationOverlap of Autoimmune Hepatitis and Primary Biliary Cirrhosis: Long-Term Outcomes
Silveira, M. G., Talwalkar, J. A., Angulo, P., & Lindor, K. D. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01136.x · Cited by 165
Codoñer-Franch, P., Tavárez-Alonso, S., Simó-Jordá, R., Laporta-Martín, P., Carratalá-Calvo, A., & Alonso-Iglesias, E. (2012) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2012.04.046 · Cited by 135
Talwalkar, J. A., Keach, J. C., Angulo, P., & Lindor, K. D. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05703.x · Cited by 127
Kido, M., Watanabe, N., Okazaki, T., Akamatsu, T., Tanaka, J., Saga, K., Nishio, A., Honjo, T., & Chiba, T. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.042 · Cited by 119
Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis
Neuhauser, M., Bjornsson, E., Treeprasertsuk, S., Enders, F., Silveira, M., Talwalkar, J., & Lindor, K. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.616 · Cited by 116
Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases
Roozendaal, C., Jong, M. A. D., Berg, A. P. V. D., Wijk, R. T. V., Limburg, P. C., & Kallenberg, C. G. M. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80241-x · Cited by 100
Cholestatic phenotypes of autoimmune hepatitis
Czaja, A. J. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.08.039 · Cited by 63 · cited 6×
“Antinuclear antibodies are present in 20% to 40% of patients with alcoholic liver disease, NAFLD, chronic viral hepatitis, PBC or PSC.156-158 Smooth muscle antibodies occur in 3% to 16% of patients with alcoholic liver disease, NAFLD, chronic hepatitis C, PBC or PSC.156-158 Each autoantibody has low sensitivity for th…”
BackgroundInfluentialSelf-citation
Cited by
Mack, C. L., Adams, D., Assis, D. N., Kerkar, N., Manns, M. P., Mayo, M. J., Vierling, J. M., Alsawas, M., Murad, M. H., & Czaja, A. J. (2020) · Hepatology · doi:10.1002/hep.31065 · Cited by 983
“AIH is asymptomatic in 25%-34% of patients.(60,104,130) Asymptomatic patients infrequently achieve spontaneous laboratory improvement (12%),(131) may have histological findings similar to those of symptomatic patients,(130) frequently develop symptoms within 2-120 months (mean interval, 32 months; 26%-70%),(104,130) a…”
BackgroundSelf-citationWeber, S., Benesic, A., Rotter, I., & Gerbes, A. L. (2019) · Liver International · doi:10.1111/liv.14195 · Cited by 53
Metadata
- Authors
- Czaja, A. J.
- Venue
- Gut and Liver
- Published
- 2016-03-23
- Volume
- 10
- Issue
- 2
- Pages
- 177
- ISSN
- 1976-2283 (ISSN-L)
- 2005-1212
- OpenAlex
- W2288437348
- Cited by
- 183
- References
- 19
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.